News

January 5, 2018

Palatin to Start Clinical Trials of Ulcerative Colitis Therapy After FDA Sign-off

News

Palatin Technologies plans to start clinical trials of its ulcerative colitis therapy PL-8177 in the next three months. The U.S. Food and Drug Administration’s decision to accept Palatin’s Investigational New Drug application for the treatment opened ... Read more

January 4, 2018January 4, 2018

Protalix Therapy Eliminates Ulcerative Colitis in a Third of Patients in Phase 2 Trial

News

Protalix BioTherapeutics’ ulcerative colitis therapy OPRX-106 eradicated the disease in a third of the first 14 patients participating in a Phase 2 clinical trial. Fifty-seven percent of the patients responded to the treatment ... Read more

January 3, 2018

Study on Protein Receptor’s Role in IBD Supports Decision to Develop Blocking Therapy, OSE Says

News

A study that OSE Immunotherapeutics conducted on the role that a protein receptor plays in bowel disease supports its development of a treatment that blocks the receptor, the company reports. It designed OSE-127 ... Read more

January 2, 2018

Defective MDR1 Gene May Promote Ileal Crohn’s Disease, Study Suggests

News

Researchers have found that the MDR1 gene helps protect immune cells from the damaging effects of bile acids in the intestine, preventing a condition known as ileal Crohn’s disease. The findings ... Read more

December 22, 2017December 22, 2017

Ionis Brings Treatment for Gastrointestinal Immune Disorders to Clinical-trial Stage

News

Janssen Biotech plans a Phase 1 clinical trial of a therapy that its partner Ionis Pharmaceuticals developed as a treatment for gastrointestinal immune disorders. Under their collaboration agreement, Ionis received $5 million for bringing ... Read more

December 21, 2017

Boehringer Ingelheim, Roche Partnering on New Class of Bowel Disease Therapies

News

Boehringer Ingelheim and Roche are teaming up to develop a new class of inflammatory bowel diseases treatments. The partners will be focusing on therapies based on an innovative approach called Locked Nucleic ... Read more

December 20, 2017

Alofisel for Crohn’s Fistulas Receives EMA Recommendation for Marketing Authorization in EU

News

TiGenix received a European Medicines Agency (EMA) recommendation for the marketing authorization of Alofisel (darvadstrocel, Cx601) as an advanced therapy medicinal product (ATMP) for the treatment of complex perianal fistulas in people with ... Read more

December 19, 2017December 19, 2017

Study Identifies How Many Missed Doses of Humira or Cimzia Can Cause an IBD Flare-up

News

Inflammatory bowel disease patients taking the biologicals Humira or Cimzia (certolizumab) are at significant risk of flare-ups if they delay refilling their prescriptions for more than two days out of two weeks, ... Read more

December 18, 2017December 18, 2017

Variation in Single Gene May Determine Response to Humira in IBD Patients, Study Reports

News

A single variation in the DNA sequence of a particular gene, called ATG16L1, was associated with response to Humira (adalimumab) treatment in a group of people with inflammatory bowel disease ... Read more

December 15, 2017

Vedanta Granted Four U.S. Patents for Therapeutics Based on Beneficial Gut Bacteria

News

Vedanta Biosciences has recently been granted four U.S. patents covering pharmaceutical compositions of therapeutics targeting inflammatory bowel disease (IBD) and other immune-mediated and infectious conditions. The new patents protect Vedanta’s therapeutic ... Read more